## Abstract Survivor costs are those costs associated with a treatment because it extends the patient's life. A controversy exists regarding whether survivor consumption costs should be included in cost–utility analyses. The present paper uses this controversy to motivate a general reexamination of
Should histological terms be included in a revision of the BNA?
✍ Scribed by Krikman, H. ;Bacon, R. L. ;Bassett, D. L. ;Danforth, C. H. ;Gray, D. J. ;Greulich, W. W. ;Turner, R. S.
- Publisher
- John Wiley and Sons
- Year
- 1945
- Tongue
- English
- Weight
- 508 KB
- Volume
- 93
- Category
- Article
- ISSN
- 0003-276X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Shorter duration and lower dose of peginterferon alfa-2a therapy results in inferior HBeAg seroconversion rates compared with the duration and dose of 48 weeks and 180 lg: NEPTUNE study.
In this editorial, I raise some questions on the power of the researcher to choose whether to be an agent of change while engaged in research involving
## Abstract ## Objective In 2005, 27% of adults reported doctor‐diagnosed arthritis, and 14% reported chronic joint symptoms but no doctor‐diagnosed arthritis (i.e., possible arthritis). We evaluate the value of including persons classified as having possible arthritis in surveillance of arthritis